← boardnext 2027-03
URGN
UroGen Pharma Ltd.distress 5/10 · elevated risk$41.53-1%today-5% from 52w high
Oncology 2
Lead: Urothelial Carcinoma
Revenue
$51M
Liquidity
$150M
Runway
0.9 yrs
Shares 1y
+5%
Price & events
+107.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.3%
1D
+3.8%
1W
+18.2%
1M
+70.8%
3M
+107.6%
6M
+122.6%
1Y
+145.2%
2Y
+171.4%
5Y
+130.9%
All
Overview
- Market Cap
- $2.02B
- Enterprise Value
- $2.10B
- Volume
- 27.36K
- 52 Week Range
- $14.04 – $43.78
- Total Shares
- 48.72M
- Float Shares
- 43.20M
- Short %
- 13.02%
- % Held by Insiders
- 3.62%
- % Held by Institutions
- 101.01%
- RVOL
- 0.04x
- Beta
- 1.57
Pipeline stages · 1 programs
UGN-104
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-03 Estimated 50% readout ~2027-05-15 | Phase 3 | UGN-104 | Upper Urinary Tract Urothelial Carcinoma, Urothelial Carcinoma | — | recruiting |
| 2026-01-09 | Phase 1 | UGN-301, UGN-201, Gemcitabine | Non-muscle Invasive Bladder Cancer, NMIBC, Carcinoma in Situ of Bladder, Bladder Cancer, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent | 51 | completed |
| 2025-09-11 | Phase 3 | UGN-103 | Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder | 99 | active not recruiting |
Catalyst news & presentations · 3
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- 2026-06-02partnershipJelmyto · Settlement and license agreement with Teva for generic version of Jelmyto, effective September 15, 2030, subject to FDA approval.SEC 8-K
- June 13, 2025PDUFAPDUFAUGN-102 · PDUFA target action date for UGN-102SEC 8-K
Approved drugs (2)
- ZUSDURIMITOMYCIN2025 · Prescription
- JELMYTOMITOMYCIN2020 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $42 (+0% upside) · 8 analysts
- 2026-07-21GuggenheimBuy
- 2026-07-16OppenheimerOutperform → Outperformer
- 2026-06-03HC Wainwright & Co.Buy
- 2026-05-18HC Wainwright & Co.Buy
- 2026-05-11HC Wainwright & Co.Buy
- 2026-05-07OppenheimerOutperform
Competitors — Urothelial Carcinoma
- MRKMerck & Co., Inc.$318.8B · D3
- PFEPFIZER INC$142.2B · D3
- BEIGFBeOne Medicines Ltd.$31.7B · D1
- JAZZJazz Pharmaceuticals plc$15.7B · D0
- NRIXNurix Therapeutics, Inc.$2.4B · D6
- TYRATyra Biosciences, Inc.$1.8B · D3
- XNCRXencor Inc$1.4B · D4
- MNPRMonopar Therapeutics$687M · D1
- NTHINEONC TECHNOLOGIES HOLDINGS, INC.$91M · D9
- AKTSAktis Oncology, Inc.— · D1
Recent news
- 2026-07-23Price to earnings forward of UroGen Pharma Ltd. – FWB:UR8 - TradingView
- 2026-07-22(URGN) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
- 2026-07-21URGN Maintained by Guggenheim -- Price Target Raised to $42 - GuruFocus
- 2026-07-21URGN Maintained by Guggenheim -- Price Target Raised to $42 - GuruFocus
- 2026-07-21URGN stock trades steady as UroGen revenue grows and pipeline advances - Ad-hoc-news.de
- 2026-07-21Enterprise value to revenue forward of UroGen Pharma Ltd. – MUN:UR8 - TradingView
- 2026-07-20Price to sales forward of UroGen Pharma Ltd. – NASDAQ:URGN - TradingView
- 2026-07-20UroGen Pharma: Reimbursement Is Turning Zusduri Into A Workflow Moat (NASDAQ:URGN) - Seeking Alpha
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.